Treatment Of Alzheimer's Disease [tratamento Da Doença De Alzheimer]

dc.creatordo Vale F.A.C.
dc.creatorNeto Y.C.
dc.creatorBertolucci P.H.F.
dc.creatorMachado J.C.B.
dc.creatorda Silva D.J.
dc.creatorAllam N.
dc.creatorBalthazar M.L.F.
dc.date2011
dc.date2015-06-30T20:23:32Z
dc.date2015-11-26T14:48:55Z
dc.date2015-06-30T20:23:32Z
dc.date2015-11-26T14:48:55Z
dc.date.accessioned2018-03-28T21:59:48Z
dc.date.available2018-03-28T21:59:48Z
dc.identifier
dc.identifierDementia E Neuropsychologia. , v. 5, n. SUPPL. 1, p. 34 - 48, 2011.
dc.identifier19805764
dc.identifier
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-79960078064&partnerID=40&md5=b7625cac8139986d57c6f19e4db8da05
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/107773
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/107773
dc.identifier2-s2.0-79960078064
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1253748
dc.description[No abstract available]
dc.description5
dc.descriptionSUPPL. 1
dc.description34
dc.description48
dc.descriptionEngelhardt, E., Brucki, S.M., Cavalcanti, J.L., Forlenza, O.V., Laks, J., Vale, F.A., Treatment of Alzheimer's disease: Recommendations and suggestions of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology (2005) Arq Neuropsiquiatr, 63, pp. 1104-1112. , Departamento de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia
dc.descriptionGronseth, G., French, J., Practice parameters and technology assessments: What they are, what they are not, and why you should care (2008) Neurology, 71, pp. 1639-643
dc.descriptionFrench, J., Gronseth, G., Lost in a jungle of evidence: We need a compass (2008) Neurology, 71, pp. 1634-1638
dc.descriptionMcKhann, G.M., Knopman, D.S., Chertkow, H., The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup (2011) Alzheimers Dement, 7, pp. 263-269
dc.descriptionMcKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease (1984) Neurology, 34, pp. 939-944
dc.descriptionAlbert, M.S., Dekosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, N.C., (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association workgroup, , Alzheimers Dement Apr 20
dc.descriptionSperling, R.A., Aisen, P.S., Beckett, L.A., Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup (2011) Alzheimers Dement, 7, pp. 280-292
dc.descriptionNordberg, A., Nicotinic receptor abnormalities of Alzheimer's disease: Therapeutic implications (2001) Biol Psychiatry, 49, pp. 200-210
dc.descriptionPeters, B.H., Levin, H.S., Effects of physostigmine and lecitin on memory in Alzheimer's disease (1979) Ann Neurol, 6, pp. 219-221
dc.descriptionSummers, W.K., Majovski, L.V., Marsh, G.M., Tachiki, K., Kling, A., Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type (1986) N Engl J Med, 315, pp. 1241-1245
dc.descriptionCorey-Bloom, J., Anand, R., Veach, J., A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetyl-chonesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease (1998) Int. J Geriatr Psychopharmacol, 1, pp. 55-65
dc.descriptionRogers, S.L., Farlow, M.R., Doody, R.S., Mohs, R., Friedhoff, L.T., A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group (1998) Neurology, 50, pp. 136-145
dc.descriptionRaskind, M.A., Peskind, E.R., Wessel, T., Yuan, W., Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group (2000) Neurology, 54, pp. 2261-2268
dc.descriptionHansen, R.A., Gartlehner, G., Webb, A.P., Morgan, L.C., Moore, C.G., Jonas, D.E., Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: A systematic review and meta-analysis (2008) Clin Interv Aging, 3, pp. 211-225
dc.descriptionLockhart, I.A., Mitchell, S.A., Kelly, S., Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: Systematic review of the "real-world" evidence (2009) Dement Geriatr Cogn Disord, 28, pp. 389-403
dc.descriptionWinblad, B., Gauthier, S., Scinto, L., Safety and efficacy of galantamine in subjects with mild cognitive impairment (2008) Neurology, 70, pp. 2024-2035. , GAL-INT-11/18 Study Group
dc.descriptionBurns, A., Bernabei, R., Bullock, R., Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the CERAD study): A randomized, placebo-controlled, double-blind trial (2009) Lancet Neurol, 8, pp. 39-47
dc.descriptionFarlow, M.R., Grossberg, G.T., Meng, X., Olin, J., Somogyi, M., (2010) Rivastigmine transdermal patch and capsule in Alzheimer's disease: Influence of disease stage on response to therapy, , Int J Geriatr Psychiatry Dec 23. [Epub ahead of print]
dc.descriptionWinblad, B., Black, S.E., Homma, A., Donepezil treatment in severe Alzheimer's disease: A pooled analysis of three clinical trials (2009) Curr Med Res Opin, 25, pp. 2577-2587
dc.descriptionJarvis, B., Figgitt, D.P., Memantine (2003) Drugs Aging, 20 (6), pp. 465-76. , discussion 477-8
dc.descriptionReisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., Möbius, H.J., Memantine in moderate-to-severe Alzheimer's disease (2003) N Engl J Med, 348, pp. 1333-1341. , Memantine Study Group
dc.descriptionTariot, P.N., Farlow, M.R., Grossberg, G.T., Graham, S.M., McDonald, S., Gergel, I., Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial (2004) JAMA, 291, pp. 317-324. , Memantine Study Group
dc.descriptionWinblad, B., Jones, R.W., Wirth, Y., Stoffler, A., Mobius, H.J., Memantine in moderate to severe Alzheimer's disease: A meta-analysis of randomised clinical trials (2007) Dement Geriatr Cogn Disord, 24, pp. 20-27
dc.descriptionAtri, A., Shaughnessy, L.W., Locascio, J.J., Growdon, J.H., Long-term course and effectiveness of combination therapy in Alzheimer disease (2008) Alzheimer Dis Assoc Disord, 22, pp. 209-221
dc.descriptionShua-Haim, J., Smith, J., Picard, F., Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: An open-label, crossover, single-centre study (2008) Clin Drug Investig, 28, pp. 361-374
dc.descriptionGrossberg, G.T., Edwards, K.R., Zhao, Q., Rationale for combination therapy with galantamine and memantine in Alzheimer's disease (2006) J Clin Pharmacol, 46 (7 SUPPL. 1), pp. S17-S26
dc.descriptionZhu, C.W., Livote, E.E., Kahle-Wrobleski, K., (2010) Longitudinal medication usage in Alzheimer disease patients, , Alzheimer Dis Assoc Disord Jul 9
dc.descriptionMcShane, R., Areosa, S.A.N.M., Memantine for dementia (2011) Cochrane Database of Systematic Reviews, p. 003154
dc.descriptionPeskind, E.R., Potkin, S.G., Pomara, N., Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial (2006) Am J Geriatr Psychiatry, 14, pp. 704-715
dc.descriptionPorsteinsson, A.P., Grossberg, G.T., Mintzer, J., Olin, J.T., Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: A randomized, double-blind, placebo-controlled trial (2008) Curr Alzheimer Res, 5, pp. 83-89. , Memantine MEM-MD-12 Study Group
dc.descriptionDoody, R.S., Tariot, P.N., Pfeiffer, E., Olin, J.T., Graham, S.M., Meta-analysis of six-month memantine trials in Alzheimer's disease (2007) Alzheimers Dement, 3, pp. 7-17
dc.descriptionSchneider, L.S., Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease. " Wuthering forest plots: Distinguishing the forest from the plots (2007) Alzheimers Dement, 3, pp. 18-20
dc.descriptionKnopman, D.S., Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease. " Memantine has negligible benefits in mild to moderate Alzheimer's disease (2007) Alzheimers Dement, 3, pp. 21-22
dc.descriptionSchneider, L.S., Insel, P.S., Weiner, M.W., Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative (2011) Arch Neurol, 68, pp. 58-66. , Alzheimer's Disease Neuroimaging Initiative
dc.descriptionLuo, Y., Smith, J.V., Paramasivam, V., Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761 (2002) Proc Natl Acad Sci U S A, 99, pp. 12197-202
dc.descriptionSmith, J.V., Luo, Y., Elevation of oxidative free radicals in Alzheimer's disease models can be attenuated by Ginkgo biloba extract EGb 761 (2003) J Alzheimers Dis, 5, pp. 287-300
dc.descriptionMix, J.A., Crews Jr., W.D., A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: Neuropsychological findings (2002) Hum Psychopharmacol, 17, pp. 267-277
dc.descriptionBirks, J., Evans, G., Ginkgo biloba for cognitive impairment and dementia (2009) Cochrane Database Syst Rev, (1), pp. CD003120
dc.descriptionDodge, H.H., Zitzelberger, T., Oken, B.S., Howieson, D., Kaye, J., A randomized placebo-controlled trial of ginkgo biloba for the prevention of cognitive decline (2008) Neurology, 70, pp. 1809-1817
dc.descriptionde Kosky, S.T., Williamson, J.D., Fitzpatrick, A.L., Ginkgo biloba for prevention of dementia: A randomized controlled trial (2008) JAMA, 300, pp. 2253-2262. , Ginkgo Evaluation of Memory (GEM) Study Investigators
dc.descriptionSnitz, B.E., O'Meara, E.S., Carlson, M.C., Ginkgo biloba for preventing cognitive decline in older adults: A randomized trial (2009) JAMA, 302, pp. 2663-2670. , Ginkgo Evaluation of Memory (GEM) Study Investigators
dc.descriptionBerman, K., Brodaty, H., Tocopherol (vitamin E) in Alzheimer's disease and other neurodegenerative disorders (2004) CNS Drugs, 18, pp. 807-825
dc.descriptionMorris, M.C., Evans, D.A., Bienias, J.L., Tangney, C.C., Wilson, R.S., Vitamin E and cognitive decline in older persons (2002) Arch Neurol, 59, pp. 1125-1132
dc.descriptionSano, M., Ernesto, C., Thomas, R.G., A controlled trial of selegiline, alphatocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease Cooperative Study (1997) N Engl J Med, 336, pp. 1216-1222
dc.descriptionPetersen, R.C., Thomas, R.G., Grundman, M., Vitamin E and donepezil for the treatment of mild cognitive impairment (2005) N Engl J Med, 352, pp. 2379-2388. , Alzheimer's Disease Cooperative Study Group
dc.descriptionIsaac, M.G., Quinn, R., Tabet, N., Vitamin E for Alzheimer disease and mild cognitive impairment (2008) Cochrane Database Syst Rev, (3), pp. CD002854
dc.descriptionMiller III, E.R., Pastor-Barriuso, R., Dalal, D., Riemersma, R.A., Appel, L.J., Guallar, E., Meta-analysis: High dosage vitamin E supplemention may increase all-cause mortality (2005) Ann Intern Med, 142, pp. 37-46
dc.descriptionDysken, M.W., Kirk, L.N., Kuskowski, M., Changes in vitamin E prescribing for Alzheimer patients (2009) Am J Geriatr Psychiatry, 17, pp. 621-624
dc.descriptionBirks, J., Flicker, L., Selegiline for Alzheimer's disease (2003) Cochrane Database Syst Rev, (1). , CD000442
dc.descriptionIrving, G.F., Freund-Levi, Y., Eriksdotter-Jönhagen, M., Omega-3 Fatty Acid Supplementation Effects on Weight and Appetite in Patients with Alzheimer's Disease: The omega-3 Alzheimer's Disease Study (2009) J Am Geriatr Soc, 57, pp. 11-17
dc.descriptionLim, W.S., Gammack, J.K., van Niekerk, J., Dangour, A.D., Omega 3 fatty acid for the prevention of dementia (2006) Cochrane Database Syst Rev, (1). , CD005379
dc.descriptionFreund-Levi, Y., Basun, H., Cederholm, T., Omega-3 supplementation in mild to moderate Alzheimer's disease: Effects on neuropsychiatric symptoms (2008) Int J Geriatr Psychiatry, 23, pp. 161-169
dc.descriptionDangour, A.D., Whitehouse, P.J., Rafferty, K., B-vitamins and fatty acids in the prevention and treatment of Alzheimer's disease and dementia: A systematic review (2010) J Alzheimers Dis, 22, pp. 205-224
dc.descriptionAisen, P.S., Schneider, L.S., Sano, M., High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: A randomized controlled trial (2008) JAMA, 300, pp. 1774-1783. , Alzheimer Disease Cooperative Study
dc.descriptionFord, A.H., Flicker, L., Alfonso, H., Vitamins B(12), B(6), and folic acid for cognition in older men (2010) Neurology, 75, pp. 1540-1547
dc.descriptionMalouf, R., Grimley Evans, J., Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people (2008) Cochrane Database Syst Rev, (4). , CD004514
dc.descriptionHenderson, V.W., Paganini-Hill, A., Miller, B.L., Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial (2000) Neurology, 54, pp. 295-301
dc.descriptionMulnard, R.A., Cotman, C.W., Kawas, C., Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. Alzheimer's disease Cooperative Study (2000) JAMA, 283, pp. 1007-1015
dc.descriptionShumaker, S.A., Legault, C., Rapp, S.R., Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial (2003) JAMA, 289, pp. 2651-2662. , WHIMS Investigators
dc.descriptionShumaker, S.A., Legault, C., Kuller, L., Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study (2004) JAMA, 291, pp. 2947-2958. , Women's Health Initiative Memory Study
dc.descriptionHenderson, V.W., Estrogen-containing hormone therapy and Alzheimer's disease risk: Understanding discrepant inferences from observational and experimental research (2006) Neuroscience, 138, pp. 1031-1039
dc.descriptionSano, M., Jacobs, D., Andrews, H., A multi-center, randomized, double blind placebo-controlled trial of estrogens to prevent Alzheimer's disease and loss of memory in women: Design and baseline characteristics (2008) Clin Trials, 5, pp. 523-533
dc.descriptionVeld, B.A., Ruitenberg, A., Hofman, A., Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease (2001) N Engl J Med, 345, pp. 1515-1521
dc.descriptionAisen, P.S., Schafer, K.A., Grundman, M., Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial (2003) JAMA, 289, pp. 2819-2826. , Alzheimer's Disease Cooperative Study
dc.descriptionTabet, N., Feldmand, H., Ibuprofen for Alzheimer's disease (2003) Cochrane Database Syst Rev, (2). , CD004031
dc.descriptionde Jong, D., Jansen, R., Hoefnagels, W., No effect of one-year treatment with indomethacin on Alzheimer's disease progression: A randomized controlled trial (2008) PLoS One, 3, pp. e1475
dc.descriptionMartin, B.K., Szekely, C., Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): Results of a randomized, controlled trial of naproxen and celecoxib (2008) Arch Neurol, 65, pp. 896-905. , ADAPT Research Group
dc.descriptionLi, G., Higdon, R., Kukull, W.A., Statin therapy and risk of dementia in the elderly: A community-based prospective cohort study (2004) Neurology, 63, pp. 1624-1628
dc.descriptionZamrini, E., McGwin, G., Roseman, J.M., Association between statin use and Alzheimer's disease (2004) Neuroepidemiology, 23, pp. 94-98
dc.descriptionZhou, B., Teramukai, S., Fukushima, M., Prevention and treatment of dementia or Alzheimer's disease by statins: A meta-analysis (2007) Dement Geriatr Cogn Disord, 23, pp. 194-201
dc.descriptionFeldman, H.H., Doody, R.S., Kivipelto, M., Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe (2010) Neurology, 74, pp. 956-964. , LEADe Investigators
dc.descriptionMcGuinness, B., O'Hare, J., Craig, D., Bullock, R., Malouf, R., Passmore, P., Statins for the treatment of dementia (2010) Cochrane Database Syst Rev, (8). , CD007514
dc.descriptionvan Paasschen, J., Clare, L., Woods, R.T., Linden, D.E., Can we change brain functioning with cognition-focused interventions in Alzheimer's disease? The role of functional neuroimaging (2009) Restor Neurol Neurosci, 27, pp. 473-491
dc.descriptionChapman, S.B., Weiner, M.F., Rackley, A., Hynan, L.S., Zientz, J., Effects of cognitive-communication stimulation for Alzheimer's disease patients treated with donepezil (2004) J Speech Lang Hear Res, 47, pp. 1149-1163
dc.descriptionRequena, C., Maestú, F., Campo, P., Fernández, A., Ortiz, T., Effects of cholinergic drugs and cognitive training on dementia: 2-year follow-up (2006) Dement Geriatr Cogn Disord, 22, pp. 339-345
dc.descriptionOlazarán, J., Reisberg, B., Clare, L., Nonpharmacological therapies in Alzheimer's disease: A systematic review of efficacy (2010) Dement Geriatr Cogn Disord, 30, pp. 161-178
dc.descriptionCotelli, M., Calabria, M., Zanetti, O., Cognitive rehabilitation in Alzheimer's disease (2006) Aging Clin Exp Res, 18, pp. 141-143
dc.descriptionOnder, G., Zanetti, O., Giacobini, E., Reality orientation therapy combined with cholinesterase inhibitors in Alzheimer's disease: Randomised controlled trial (2005) Br J Psychiatry, 187, pp. 450-455
dc.descriptionYamaguchi, H., Maki, Y., Yamagami, T., Overview of non-pharmacological intervention for dementia and principles of brain-activating rehabilitation (2010) Psychogeriatrics, 10, pp. 206-213
dc.descriptionHaslam, C., Gilroy, D., Black, S., Beesley, T., How successful is errorless learning in supporting memory for high and low-level knowledge in dementia? (2006) Neuropsychol Rehabil, 16, pp. 505-536
dc.descriptionRothi, L.J., Fuller, R., Leon, S.A., Errorless practice as a possible adjuvant to donepezil in Alzheimer's disease (2009) J Int Neuropsychol Soc, 15, pp. 311-322
dc.descriptionYu, F., Rose, K.M., Burgener, S.C., Cognitive training for early-stage Alzheimer's disease and dementia (2009) J Gerontol Nurs, 35, pp. 23-29
dc.descriptionHogan, D.B., Bailey, P., Black, S., Diagnosis and treatment of dementia: Nonpharmacologic and pharmacologic therapy for mild to moderate dementia (2008) CMAJ, 179, pp. 1019-1026
dc.descriptionHeyn, P., Abreu, B.C., Ottenbacher, K.J., The effects of exercise training on elderly persons with cognitive impairment and dementia: A meta-analysis (2004) Arch Phys Med Rehabil, 85, pp. 1694-1704
dc.descriptionLautenschlager, N.T., Cox, K., Kurz, A.F., Physical activity and mild cognitive impairment and Alzheimer's disease (2010) Curr Neurol Neurosci Rep, 10, pp. 352-358
dc.descriptionForbes, D., Forbes, S., Morgan, D.G., Markle-Reid, M., Wood, J., Culum, I., Physical activity programs for persons with dementia (2008) Cochrane Database Syst Rev, (3). , CD006489
dc.descriptionRolland, Y., Pillard, F., Klapouszczak, A., Exercise program for nursing home residents with Alzheimer's disease: A 1-year randomized, controlled trial (2007) J Am Geriatr Soc, 55, pp. 158-165
dc.descriptionApostolova, L.G., Cummings, J.L., Neuropsychiatric manifestations in mild cognitive impairment: A systematic review of the literature (2008) Dement Geriatr Cogn Disord, 25, pp. 115-126
dc.descriptionFillit, H.M., The pharmacoeconomics of Alzheimer's disease (2000) Am J Manag Care, 6 (22 SUPPL.), pp. S1139-S1144
dc.descriptionBuhr, G.T., White, H.K., Difficult behaviors in long-term care patients with dementia (2006) J Am Med Dir Assoc, 7, pp. 180-192
dc.description(2007) Interpretive guidelines for long-term care facilities, , Department of Health and Human Services, State Operations Manual, Appendix PP-Guidance to Surveyors for Long Term Care Facilities, Accessed August 21 cms.hhs.gov/manuals/downloads/som107_pp_guidelines_ltcf.pdf
dc.descriptionShekelle, P., Maglione, M., Bagley, S., (2007) Comparative effectiveness of off-label use of atypical antipsychotics. Comparative Effectiveness Review No. 6, , Effectivehealthcare.ahrq.gov/repFiles/Atypical_Antipsychotics_Final_Report.pdf, (Prepared by the Southern California/RAND Evidence-based Practice Center under Contract 290-02-003.) Rockville, MD: Agency for Healthcare Research and Quality
dc.descriptionJanuary
dc.descriptionSultzer, D.L., Davis, S.M., Tariot, P.N., Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: Phase 1 outcomes from the CATIE-AD effectiveness trial (2008) Am J Psychiatry, 165, pp. 844-854. , CATIE-AD Study Group
dc.descriptionCarson, S., McDonagh, M.S., Peterson, K., A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia (2006) J Am Geriatr Soc, 54, pp. 354-361
dc.descriptionTran-Johnson, T.K., Sack, D.A., Marcus, R.N., Auby, P., McQuade, R.D., Oren, D.A., Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: A randomized, double-blind, placebo-controlled trial (2007) J Clin Psychiatry, 68, pp. 111-119
dc.descriptionGrossberg, G.T., Desai, A.K., Management of Alzheimer's disease (2003) J Gerontol A Biol Sci Med Sci, 58, pp. 331-353
dc.descriptionCummings, J.L., Benson, D.F., (1992) Dementia: A clinical approach, , 2nd ed. Boston, MA: Butterworth-Heinemann
dc.descriptionLyketsos, C.G., Colenda, C.C., Beck, C., Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease (2006) Am J Geriatr Psychiatry, 14, pp. 561-572. , Task Force of American Association for Geriatric Psychiatry
dc.descriptionBallard, C.G., Thomas, A., Fossey, J., A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: The neuropsychiatric inventory median cutoff is a predictor of clinical outcome (2004) J Clin Psychiatry, 65, pp. 114-119
dc.descriptionde Deyn, P.P., Katz, I.R., Brodaty, H., Lyons, B., Greenspan, A., Burns, A., Management of agitation, aggression, and psychosis associated with dementia: A pooled analysis including three randomized, placebo-controlled double blind trials in nursing home residents treated with risperidone (2005) Clin Neurol Neurosurg, 107, pp. 497-508
dc.descriptionKatz, I., de Deyn, P.P., Mintzer, J., Greenspan, A., Zhu, Y., Brodaty, H., The efficacy and safety of risperidone in the treatment of psychosis of Alzheimers disease and mixed dementia: A meta-analysis of 4 placebo controlled clinical trials (2007) Int J Geriatr Psychiatry, 22, pp. 475-484
dc.descriptionSchneider, L.S., Dagerman, K.S., Insel, P., Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials (2005) JAMA, 294, pp. 1934-1943
dc.descriptionSink, K.M., Holden, K.F., Yaffe, K., Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence (2005) JAMA, 293, pp. 596-608
dc.descriptionGuidelines abstracted from the American Academy of Neurology's dementia guidelines for early detection, diagnosis and management of dementia (2003) J Am Geriatr Soc, 51, pp. 869-873. , AGS Clinical Practice Committee
dc.descriptionBallard, C., Lana, M.M., Theodoulou, M., A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial) (2008) PLoS Med, 5, pp. e76. , Investigators DART AD
dc.descriptionSink, K.M., Holden, K.F., Yaffe, K., Pharmacologic treatment of neuropsychiatric symptoms of dementia: A review of the evidence (2005) JAMA, 293, pp. 596-608
dc.description(2005) AAGP Atypical Position Statement, , http://www.aagponline.org/prof/antipsychstat_0705.asp, American Academy for Geriatric Psychiatry, Retrieved March 26, 2008, from
dc.descriptionMadhusoodanan, S., Shah, P., Brenner, R., Gupta, S., Pharmacological treatment of the psychosis of Alzheimer's disease: What is the best approach? (2007) CNS Drugs, 21, pp. 101-115
dc.descriptionTrinh, N., Hoblyn, J., Mohanty, S., Yaffe, K., Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease a meta-analysis (2003) JAMA, 289, pp. 210-216
dc.descriptionLoy, C., Schneider, L., Galantamine for Alzheimer's disease and mild cognitive impairment (2006) Cochrane Database Syst Rev, (1). , CD001747
dc.descriptionCummings, J.L., Schneider, L., Tariot, P.N., Kershaw, P.R., Yuan, W., Reduction of behavioral disturbances and caregivers distress by galantamine in patients with Alzheimer's disease (2004) Am J Psychiatry, 161, pp. 532-538
dc.descriptionBirks, J., Grimley, E.J., Iakovidou, V., Tsolaki, M., Rivastigmine for Alzheimer's disease (2000) Cochrane Database Syst Rev, (4). , CD001191
dc.descriptionBirks, J., Harvey, R., Donepezil for dementia due to Alzheimer's disease (2006) Cochrane Database Syst Rev, (1). , CD001190
dc.descriptionGauthier, S., Feldman, H., Hecker, J., Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease (2002) Int Psychogeriatr, 14, pp. 389-404. , Donepezil MSAD Study Investigators Group
dc.descriptionFeldman, H., Gauthier, S., Hecker, J., Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: A subgroup analysis from a randomized, placebo-controlled trial (2005) Int J Geriatr Psychiatry, 20, pp. 559-569. , Donepezil MSAD Study Investigators Group
dc.descriptionHolmes, C., Wilkinson, D., Dean, C., The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease (2004) Neurology, 63, pp. 214-219
dc.descriptionHoward, R.J., Juszczak, E., Ballard, C.G., Donepezil for the treatment of agitation in Alzheimer's disease (2007) N Engl J Med, 357, pp. 1382-1392. , CALM-AD Trial Group
dc.descriptionCummings, J.L., Schneider, E., Tariot, P.N., Graham, S.M., Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment (2006) Neurology, 67, pp. 57-63. , Memantine MEM-MD-02 Study Group
dc.descriptionKonovalov, S., Muralle, S., Tampi, R.R., Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: A literature review (2008) Int Psychogeriatr, 20, pp. 293-308
dc.descriptionTariot, P.N., Erb, R., Podgorski, C.A., Efficacy and tolerability of carbamazepine for agitation and aggression in dementia (1998) Am J Psychiatry, 155, pp. 54-61
dc.descriptionSeitz, D.P., Adunuri, N., Gill, S.S., Gruneir, A., Herrmann, N., Rochon, P., Antidepressants for agitation and psychosis in dementia (2011) Cochrane Database Syst Rev, 2. , CD008191
dc.descriptionWeintraub, D., Rosenberg, P.B., Drye, L.T., Sertraline for the treatment of depression in Alzheimer's disease: Week-24 outcomes (2010) Am J Geriatr Psychiatry, 18, pp. 332-340. , DIADS-2 Research Group
dc.descriptionLyketsos, C.G., del Campo, L., Steinberg, M., Treating depression in Alzheimer disease: Efficacy and safety of sertraline therapy, and the benefits of depression reduction: The DIADS (2003) Arch Gen Psychiatry, 60, pp. 737-746
dc.descriptionFinkel, S.I., Mintzer, J.E., Dysken, M., Krishnan, K.R., Burt, T., McRae, T., A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil (2004) Int J Geriatr Psychiatry, 19, pp. 9-18
dc.descriptionNyth, A.L., Gerhard, G., The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: A Nordic multicenter study (1990) Br J Psychiatry, 157, pp. 894-901
dc.descriptionPollock, B.G., Mulsant, B.H., Rosen, J., Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients (2002) Am J Psychiatry, 159, pp. 460-465
dc.descriptionSultzer, D.L., Gray, K.F., Gunay, I., Wheatley, M.V., Mahler, M.E., Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia? (2001) J Am Geriatr Soc, 49, pp. 1294-1300
dc.descriptionBarak, Y., Plopski, I., Tadger, S., Paleacu, D., Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: A randomized double-blind pilot study (2011) Int Psychogeriatr, pp. 1-5
dc.descriptionChibnall, J.T., Tait, R.C., Harman, B., Luebbert, R.A., Effect of acetaminophen on behavior, well-being, and psychotropic medication use in nursing home residents with moderate-to-severe dementia (2005) J Am Geriatr Soc, 53, pp. 1921-1929
dc.descriptionLu, P.H., Masterman, D.A., Mulnard, R., Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and health elderly men (2006) Arch Neurol, 63, pp. 177-185
dc.descriptionGehrman, P.R., Connor, D.J., Martin, J.L., Shochat, T., Corey-Bloom, J., Ancoli-Israel, S., Melatonin fails to improve sleep or agitation in a double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer's disease (2009) Am J Geriatr Psychiatry, 17, pp. 166-169
dc.descriptionScripnikov, A., Khomenko, A., Napryeyenko, O., Effects of ginkgo biloba extract EGb 761 on neuropsychiatric symptoms of dementia: Findings from a randomized controlled trial (2007) Wien Med Wochenschr, 157, pp. 295-300. , GINDEM-NP Study Group
dc.descriptionDoody, R.S., Gavrilova, S.I., Sano, M., Effect od dimebon on cognition, activities of daily living, behavior, and global function in patients with mild-to-moderate Alzheimer's disease: A randomized, double blind, placebo-controlled study (2008) Lancet, 372, pp. 207-215. , dimebon investigators
dc.descriptionBeer, C.D., Horner, B., Almeida, O.P., Dementia in residential care: Education intervention trial (DIRECT)
dc.descriptionprotocol for a randomised controlled trial (2010) Trials, 11, p. 63
dc.descriptionPerry, M., Drašković, I., Achterberg, T., Can an EASYcare based dementia training programme improve diagnostic assessment and management of dementia by general practitioners and primary care nurses? The design of a randomized controlled trial (2008) BMC Health Serv Res, 8, p. 71
dc.descriptionCerga-Pashoja, A., Lowery, D., Bhattacharya, R., Evaluation of exercise on individuals with dementia and their carers: A randomized controlled trial (2010) Trials, 11, p. 53
dc.descriptionPitkala, K.H., Raivio, M.M., Laakkonen, M., Tilvis, R.S., Kautiainen, H., Strandberg, T.E., Exercise rehabilitation on home-dwelling patients with Alzheimer's disease-a randomized, controlled trial. Study protocol (2010) Trials, 11, p. 92
dc.descriptionGraff, M.J.L., Vernooil-Dassen, M.J.M., Thijssen, M., Community based occupational therapy for patients with dementia and their care givers: Randomised controlled trial (2006) BMJ, pp. 1-6. , bmj.com Online First
dc.descriptionFerrero-Arias, J., Goñi-Imízcoz, M., González-Bernal, J., Lara-Ortega, F., da Silva-González, A., Díez-Lopez, M., (2011) The Efficacy of Nonpharmacological Treatment for Dementia-related Apathy, , Alzheimer Dis Assoc Disord [Epub ahead of print]
dc.descriptionRaglio, A., Bellelli, G., Traficante, D., Efficacy of music therapy in the treatment of behavioral and psychiatric symptoms of dementia (2008) Alzheimer Dis Assoc Disord, 22, pp. 158-162
dc.descriptionCooke, M., Moyle, W., Shum, D., Harrison, S., Murfield, J., A randomized controlled trial exploring the effect of music on quality of life and depression in older people with dementia (2010) J Health Psychol, 15, pp. 765-776
dc.languageen
dc.languagept
dc.publisher
dc.relationDementia e Neuropsychologia
dc.rightsfechado
dc.sourceScopus
dc.titleTreatment Of Alzheimer's Disease [tratamento Da Doença De Alzheimer]
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución